#News for #Investors and #Media: Today, we announced the US FDA accepted the application for one of our immuno-oncology therapies for priority review.
Learn more: gsk.to/4zAczXU
We are uniting science, technology and talent to get ahead of disease together.
Our community guidelines: gsk.to/socialmedia
- #News for #Investors and #Media: At #AIDS2026 we’re presenting new clinical and real-world insights from across our long-acting portfolio and pipeline for #HIV treatment and prevention, through our specialist HIV company, @ViiVHC. Find out more: gsk.to/44YUip5
- #Investors: Join our webcast (14:00 BST, 09:00 EST) to hear our CEO Luke Miels and other members of our senior leadership team including R&D experts talk about our Q2 2026 results and plans to accelerate growth. $GSK

